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ABSTRACT  
 
This quantitative, descriptive study investigated risk factors for MDR-TB in Addis Ababa, 
Ethiopia. A total of 439 medical records belonging to MDR-TB and non MDR-TB patients 
managed in public health centres from January 2008 to December 2011 were analysed. 
Data were transcribed from each TB patient‟s medical records using a specifically 
designed checklist. 
 
 The findings revealed that male gender, previous history of TB treatment, poor treatment 
adherence, an outcome of failure after TB re-treatment, previous category of failure, 
pulmonary involvement of TB infection and HIV infection were associated with MDR-TB. 
The findings illustrate that efforts should be made to prioritise the development and 
implementation of effective MDR TB screening and treatment protocols for these high risk 
groups to improve treatment outcome and minimize the emergence of XDR TB.   
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CHAPTER 1 
 
Orientation to the study 
 
1.1 INTRODUCTION 
 
Tuberculosis (TB) is one of the leading causes of morbidity, the fourth causes of 
hospital admissions, and the second cause of hospital deaths in Ethiopia 
(FMOH 2009). It has been recognized as a major public health problem since 
1950. Since then control has been initiated by establishment of TB Sanatorium 
and latter strengthened by implementation of Directly Observed Treatment 
Short Course (DOTS) in the 1990s. Ethiopia has been implementing the WHO 
STOP-TB strategy since 2006.  This strategy involves scaling up of effective 
chemotherapy and intensive health education for TB patients. 
 
The continuous challenge in the occurrence and management of Multidrug-
Resistant Tuberculosis (MDR-TB) in the country prompted this study which 
seeks-to investigate the risk factors for MDR-TB. Its outcomes are believed to 
help in designing appropriate prevention and control strategies.  In doing so, 
results also indirectly improve our knowledge on Extensive Drug-Resistant 
Tuberculosis (XDR-TB) as the two share same contributing factors.  
 
1.2 BACKGROUND TO THE PROBLEM 
 
TB is a major global health problem. Globally, the absolute number of TB cases 
are increasing slowly, although the number of cases per capita (usually 
expressed as the number of cases per 100 000 population) is falling by around 
1% per year. TB ranks as the eighth leading cause of death in low- and middle-
income countries (seventh for men and ninth for women); among adults aged 
15–59, it ranks as the third cause of death, after HIV/AIDS and ischemic heart 
disease.  Each year, there are around 9 million new cases of TB, and close to 2 
million people die from the disease.  All countries are affected, but 85% of the 
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cases occur in Africa and Asia.  Africa alone accounts 30% and Asia 55%, with 
India and China alone accounting for 35% of all cases for Asia (WHO 2010:7).   
The most recent estimates of TB data from the World Health Organization 
(WHO), indicates that TB incidence declined in only 10 of 46 African countries 
between 2000 and 2007(WHO 2009a:5, 2010:32).  
 
Global control of TB has been jeopardized by two major threats: HIV/AIDS and 
MDR-TB (multi-drug resistant tuberculosis). MDR-TB is defined as strains of 
Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin 
(WHO 2008a:6). 
 
Yet TB is, in most instances, a curable disease. Using combinations of first-line 
drugs introduced into treatment between the 1950s and 1980s, around 90% of 
people with drug-susceptible TB can be cured in six months. Treatment of 
MDR-TB of which there are around 0.4–0.5 million cases each year–is more 
challenging. It requires use of second-line drugs (including injectable antibiotics) 
that are more costly and cause more severe side-effects, and recommended 
regimens must be taken for up to two years. Cure rates for MDR-TB are lower, 
typically ranging from around 50% to 70%.  Among TB patients globally notified 
in 2009, an estimated 250 000 (range, 230 000–270 000) had MDR-TB. Of 
these, slightly more than 30,000 (12%) were diagnosed with MDR-TB (WHOb 
2010:7).    
 
Drug resistant tuberculosis develops as a result of mismanagement of 
susceptible TB. The mismanagement may include inappropriate treatment 
regimens (e.g., a wrong choice of drugs, dosage and duration of treatment), 
programme factors (e.g., irregular supply, incompetent health personnel), and 
patient factors (e.g., poor adherence i.e. patients may feel better and halt their 
medication, mal-absorption) (FMOH 2011: 17).  
 
In Ethiopia, by 2008, WHO estimated the incidence MDR-TB among new TB 
cases to be 1.6 % (160 cases) and 11.8 % (5000 cases) among previously 
treated TB cases (WHO 2010b:17).   
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The Ethiopian Government has identified the MDR-TB as one of priority public 
health problems and initiated comprehensive treatment for MDR-TB cases in 
the country (FMOH 2011: 34, FMOH 2009: 6). One such measure includes 
endorsement of single procurement mechanisms for TB drugs and controlled 
use of second line anti-TB drugs since 2009.  
 
1.3 GEOGRAPHICAL AREA 
 
The study was undertaken at health facility in Addis Ababa city. Addis Ababa is 
the capital city of Ethiopia. It is the largest city in Ethiopia, with a population of 
3,384,569 according to the 2007 population census.  Addis Ababa is a 
chartered city, has the status of both a city and a state. It is where the African 
Union and its predecessor the Organization of African Unity (OAU) are based. 
Addis Ababa is therefore often referred to as "The political capital of Africa", due 
to its historical, diplomatic and political significance for the continent. The city is 
populated by people from different regions of Ethiopia – the country has as 
many as 80 nationalities speaking 80 languages and belonging to a wide variety 
of religious communities. Addis Ababa lies at an altitude of 7,546 feet (2,300 
meters) and is a grassland biome, located at 9°1′48″N 38°44′24″ECoordinates: 
9°1′48″N 38°44′24″E(Encyclopaedia of the nation‟s 2011). 
 
1.4 RATIONAL OF THE STUDY 
 
The study sought to examine the risk factors that contribute to emerging lethal 
problem of MDR-TB in Addis Ababa.   
 
1.5 STATEMENT OF THE PROBLEM  
 
A problem statement articulates the problem to be addressed and indicates the 
need for a study (Polit and Beck 2007:65). Mosley (2008:4) describes a problem 
statement as “a statement that identifies the key research variables, specifies 
the nature of the population and suggests the possibility of empirical testing”.  
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Ethiopia ranks 7th among the 22 high-burden countries and 15th in the list of 27 
countries with the highest number of estimated MDR-TB cases (WHO 2009b).    
In a study conducted by Agonafir and his colleagues (2010) in Addis Ababa, 
MDR-TB was observed in one of the 44 new cases (2.3%) and 45/63 previously 
treated patients (71.4%). Despite the rising public health concern of MDR-TB in 
the country, factors underlying for spread of this diseases is not yet determined. 
Like most TB control programmes, the National Treatment Program does not 
have the resources to perform culture and drug susceptibility testing (DST) for 
all TB patients which is true for city of Addis Ababa (FMOH 2009:15).  
Consequently, the following questions were derived from the problem 
statement:    
 
o What socio-demographic factors are associated with occurrence of 
MDR-TB in Addis Ababa? 
o Is non-adherence to anti-TB treatment associated with development 
MDR-TB? 
o Which types of TB treatment category and treatment outcomes are 
associated with multidrug-resistance? 
o Is the emergence of MDR-TB associated with HIV/AIDS in Addis 
Ababa?  
 
The problem that the researcher set himself is to make a demanding study on 
risk factors for spreading out of MDR-TB in Addis Ababa, Ethiopia. Once these 
factors are known and understood, a coherent strategy can be implemented to 
address the predicament of MDR-TB.  
 
1.6 AIM OF THE STUDY 
 
The purpose of this study is to investigate risk factors for MDR-TB in Addis 
Ababa, Ethiopia. 
 
1.6.1 Research objectives  
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o To determine the socio-demographic factors associated with MDR-TB 
among patients in Addis Ababa. 
o To determine if non adherence to treatment is associated with 
development MDR-TB. 
o To determine the types of TB treatment categories and treatment 
outcomes associated with MDR-TB.  
o To describe the association of HIV/AIDS and MDR-TB in Addis Ababa 
 
1.7 SIGNIFICANCE OF THE STUDY  
 
This study investigated the risk factors for MDR-TB in Addis Ababa, Ethiopia.  
Data on risk factors contributing for the occurrence of MDR-TB can be used in 
designing educational messages that can improve health care seeking towards 
MDR-TB.  Study findings would have potential to encourage higher health 
officials to improve current TB control program shortcomings, as well as for 
conducting further research. Finally, the findings could provide important 
information on ways to improve quality of MDR-TB care in the country.   
 
1.8 FOUNDATIONS OF THE STUDY 
 
1.8.1 Conceptual framework of the study 
 
 
 
 
 
 
Figure 1.1 Conceptual framework of the study 
 
This conceptual framework is developed after an extensive review of pertinent 
literatures on MDR-TB in developing countries (W. S. Law, W. W. Yew, C. 
Socio-Demographic 
factors:  
Age, sex, place of 
residence 
 
TB/HIV co-infection 
 
 
 
Previous history of TB: 
Previous use of TB Drug, Types of 
TB Treatment category, site of 
involvement,  
 
Patient related factors: 
Poor adherence /non 
adherence to treatment 
Risk factor 
for 
MDR-TB 
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Leung, K. M. Kam, C. M. Tam, C. K. Chan, C. C. Leung 2008:1065;  Kliiman, K 
2009: 66;  L.A. Ferguson & J. Rhoads 2009:606).  The variables included in the 
framework are believed to closely describe the realities experienced by most 
MDR-TB patients in Ethiopia.  As could be seen in the figure, this study 
examined the problem of MDR-TB from four major angles namely the socio-
demographic characteristics, patient behaviour, previous history of TB treatment 
and presence of HIV co-infection. 
 
1.9 RESEARCH DESIGN AND METHODOLOGY 
 
1.9.1 Research design 
 
Polit and beck (2007:49) defines the study design as the overall plan for 
obtaining answers to the questions being studied and for handling some of the 
difficulties encountered during the research process.  A research design is “an 
overall plan for collecting and analysing data, including specifications for 
enhancing the internal and external validity of the study” (De Vos, Strydom, 
Fouche & Delport 2002:137).  
 
Cross-sectional comparative study design was employed for this study. The 
study characterizes MDR-TB patients and compares them with non MDR-TB 
patients on socio-demographic and patient related variables (risk factors).   
 
1.9.2 Population 
 
A population is “an aggregate of people or objects with common characteristics 
of interest to the researcher” (Bowling 2002:157). In this study, the population of 
the study was all TB patients confirmed to be MDR and non MDR-TB patients in 
26 public health centres in Addis Ababa from January 2008 to December 2011. 
 
1.9.3 Sample and Sampling 
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A sample is a subset of a population selected to participate in a study. Sampling 
is the process of selecting a portion of the population to represent the entire 
population. The selected elements are then referred to as the sample (De Vos 
et al 2002:198). 
 
Risk of exposure to MDR-TB among newly confirmed TB patients was taken as 
an indicator variable in order to estimate the minimum number of cases that 
need to be sampled for the study.  According to the Federal MOH of Ethiopia, 
the risk of MDR-TB among newly confirmed TB patients is nearly 2% compared 
to 12% among re-treated TB patients (FMOH 2009:3).  
 
 A Fleiss with Continuity Correction sample size calculation formula using Open 
Epi version 2.3 for windows were used to calculate the sample size.  A marginal 
error of 3%, 80% study power, 95% confidence limit and a ratio of exposed 
(MDR) to unexposed (non-MDR) of 1:3 were assumed.   Accordingly, a total of 
400 study participants (100 MDR-TB and 300 non MDR-TB) were estimated to 
give sufficiently valid information to respond to the study questions. 10% of the 
samples were added to cater for incomplete data making the total sample size 
of 439 (113 MDR-TB and 326 non MDR-TB). 
 
The researcher used a systematic random sampling method to select non 
MDR-TB patients registered in the 26 public health centres in Addis Ababa 
between January 2008 and December 2011 and fulfilling the selection criteria 
while all MDR patients seen in the 26 public health centres were included in the 
study.  The number of non-MDR patients sampled from each health centre 
corresponded with TB case load and number of MDR-TB contributed from the 
site. TB registers were used as data source. From the registers found in each 
health centre, the ID numbers assigned to each patient seen between January 
2008 and December 2011 were listed serially and every nth non-MDR patient 
was selected for review until the required number of sample from the site is 
fulfilled. 
 
1.9.4 Data collection instrument 
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The data was collected using a standard record review form adopted from the 
registry of national TB control program containing study variables.  
 
1.9.5 Data analysis 
  
The study was quantitative therefore both descriptive and analytic statistical 
methods were applied.  The data were coded and entered in to Epi-Info version 
3.5 and exported to SPSS version 16.0. The entered data were analysed by 
statistician.  Odds ratio, chi-square test, and logistic regression were used for 
inferential statistics.  Tables, graphs, charts, and percentages were used for 
descriptive statistics.  
 
1.10. VALIDITY AND RELIABILITY 
 
1.10.1 Validity 
 
To maintain the validity of the study, conceptual and operational definitions of 
terms were used according to the objective of the study.  Records that meet 
eligibility and inclusion criteria based on clinical and laboratory results confirmed 
diagnosis were selected.  Pre-tested data abstraction forms were used.  The 
data were stratified for age and gender and multivariate analysis were 
performed during the analysis. Consultation with medical officers and nurses 
providing medical service for TB patients were done to measure the construct 
domain of the study to ensure instruments validity.  
 
1.10.2 Reliability 
 
To maintain the reliability of the study, careful training, development of a clearly 
defined standardized format after reviewing the literature, pre testing of the 
abstraction instrument and consulting experts in the field were designed and a 
small number of research assistants were used to enhance the accuracy of 
observer ratings and classifications. Only the researcher was responsible for 
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cleaning abstracted data and by so doing increased the chances of consistency 
in data collection.   
1.11 ETHICAL CONSIDERATIONS  
 
The goal of ethics in research is to ensure that no one is harmed or suffers 
adverse consequences from research activities. Chapter 3 discusses the ethical 
concerns fully.  
 
1.12 DEFINITIONS OF KEY CONCEPTS 
 
 Tuberculosis: refers to all TB types that have been confirmed by 
clinical, AFB microscopy, culture (DST) and/or radiology. 
 
 Multidrug-resistant tuberculosis (MDR-TB):  is defined as: 
▬ TB infection caused by strains of Mycobacterium tuberculosis that are 
resistant to at least isoniazid and rifampicin. 
▬ In this study, patients confirmed to be MDR and started his/her treatment 
and follow up at public health centres in Addis Ababa are included in the 
review. 
  
 Non MDR-TB/sensitive TB cases are all forms of TB which are 
sensitive to first line TB drugs. 
 Extensively drug-resistant tuberculosis (XDR-TB): is defined as 
MDR-TB plus resistance to a fluoroquinolone and at least one second-
line injectable agent: amikacin, kanamycin and/or capreomycin. 
 
 Non-adherence: a patient is categorized as treatment non-adherent if 
they missed more than 20% of the prescribed doses during the intensive 
phase of the treatment period as recommended by WHO that can be  
confirmed from TB register of the patients. This same definition is applied 
in the current study. 
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 Cured:  patient is categorizes as cured when a sputum smear becomes 
negative at, or one „month‟ prior to, the completion of treatment (at 5th 
month).  
 
 Treatment completed: when a patient has completed the treatment 
course and smear results are not available at or one month prior to the 
completion of treatment.  
 
 Defaulter: Are when a patient has been on treatment for at least 4 
weeks and whose treatment was interrupted for more than 8 consecutive 
weeks.  
 
 Treatment failure: is when a patient remains or becomes again smear-
positive at 5 months or later during treatment. 
 
 Drug resistance among new cases (Primary drug-resistance): is a 
drug resistance in a patient who has never been treated for tuberculosis 
or received less than one month of therapy. 
 
 Drug resistance among previously treated cases (Secondary or 
Acquired Drug-Resistance): is a drug resistance in a patient who has 
received at least one month of anti-TB therapy. 
 
 TB Treatment category:  
 
o Category I- are TB treatment group for new and returnees after default 
from DOTS who have smear negative Pulmonary Tuberculosis (PTB). 
o Categories II- are the treatment category for the re-treatment cases 
including returns after default from DOTS who have smear positive. 
o Category IV- MDR-TB cases (still sputum positive after supervised re-
treatment). 
 
1.13 SCOPE AND LIMITATIONS OF THE STUDY 
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The study is limited by to its design which involved secondary analysis of 
clinical data. Secondary analysis of patient records has potential for deficiency 
in the amount of information required to answer the research objectives.   
 
1.14 OUTLINE OF THE STUDY  
 
This study has 5 chapters. Chapter 1 introduces the study and briefly outlines 
the problem, purpose and significance of the study, research design and 
methodology, and ethical considerations. Chapter 2 describes the literature 
review conducted for the study. Chapter 3 discusses the research design and 
methodology. Chapter 4 presents the data analysis and interpretation, and 
findings. Chapter 5 concludes the study and makes recommendations for 
practice and further research.  
 
1.15 CONCLUSION  
 
This chapter described the background to the problem, the purpose and 
significance of the study, the research design and methodology, as well as 
ethical considerations, and defined key terms. Chapter 2 discusses the 
literature review conducted for the study. 
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CHAPTER 2 
 
Literature review 
 
2.1 INTRODUCTION      
 
A literature review is undertaken to assist researchers to comprehend and 
extend their knowledge of the phenomenon under study (Polit & Beck 
2008:105). Volmink (2007: 66) states that a literature review is indispensable if 
one wants to know (1) the current state of knowledge about any given subject, 
(2) what still needs to be studied so that the direction of future research can be 
efficiently determined, and (3) how available resources should be optimally 
allocated and distributed. This chapter discusses literature review conducted on 
risk factors for MDR-TB in Ethiopia and elsewhere. 
 
The literature review covered global epidemiology of MDR-TB, epidemiology of 
MDR-TB in Ethiopia, health care system of Ethiopia, TB prevention and control 
program in Ethiopia, and risk factors for MDR-TB.  
 
2.2 GLOBAL EPIDEMIOLOGY OF MDR-TB 
 
 In 2008, an estimated 390 000–510 000 cases of MDRTB emerged globally 
(best estimate, 440 000 cases). Among all incident TB cases globally, 3.6% 
(95% confidence interval (CI): 3.0–4.4) are estimated to have MDR-TB.  Almost 
50% of MDR-TB cases worldwide are estimated to occur in China and India.  In 
2008, MDR-TB caused an estimated 150 000 deaths (WHO 2010a: 5; 
International council of nurses 2008: 19). 
 
In 2007, the WHO reported the highest rates of MDR TB ever recorded, with up 
to 22% of new TB cases being resistant to both isoniazid and rifampicin in some 
areas of the former Soviet Union (WHO 2009b:4). 
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Seven drug susceptibility data were collected for 90,726 patients in 83 countries 
and territories from 2002 to 2007. The median prevalence of resistance in new 
cases of TB was 11.1% for any drug and 1.6% for MDR-TB. The prevalence of 
MDR-TB in new TB cases ranged from 0% in eight countries to 22.3% in Baku, 
Azerbaijan, and 19.4% in the Republic of Moldova. Of the 20 settings with the 
highest proportion of MDR-TB in new cases, 14 are located in countries of the 
former Soviet Union (between 6.8% and 22.3% in nine countries, including 
Moldovia and Azerbaijan) and four in China (7% in two provinces in China) 
(Wright A, Zignol M, Van Deun A, et al.2009: 373; WHO 2008a: 120). 
 
Countries conduct surveillance of anti-TB drug resistance as component of any 
TB control programme with four main  objectives: a) measure the burden of 
drug-resistant TB and accurately plan treatment programmes with second-line 
drugs; b) assess epidemiological trends as a reflection of the effectiveness of 
implemented drug-resistant TB prevention and control activities; c) design 
effective empirical, standardized regimens for the treatment of TB, particularly 
for patients who have already been treated for TB and return with the disease; 
and d) promptly identify local outbreaks of drug-resistant TB in order to respond 
in a timely way (WHO 2011:14).  
 
2.3 EPIDEMIOLOGY OF MDR-TB IN ETHIOPIA 
 
Ethiopia ranks 7th in the list of the world‟s 22 high burden countries for TB with 
incidence estimated at 379/100,000 for all forms of TB and 168/100,000 for 
smear positive tuberculosis. The Annual Risk of TB Infection is estimated at 
2.2% (FMOH 2009:1).  WHO 2011 TB report estimates 2,400 new MDR-TB 
cases every year in Ethiopia.                                                                                   
 
The first study on primary and initial drug resistance of Mycobacterium 
Tuberculosis in Ethiopia was reported in 1984. The study showed primary 
resistance to Isoniazid and Streptomycin to be 14.8% and 4.9%, respectively. 
Several studies were done later in Addis Ababa and in some other parts of the 
country with results showing primary or initial drug resistance to one or more 
drugs ranging from 7.6% to 32.5% (FMOH 2007:23).  
~ 14 ~ 
 
 
 According to the anti-TB drug resistance survey conducted nationwide in 2005 
by the Ethiopian Health and Nutrition Research Institute (EHNRI), among 804 
newly diagnosed TB cases, 1.6% were found to be infected with MDR-TB. The 
rate of MDR-TB among specimens from 76 previously treated TB cases was 
11.8%. Based on the prevalence rate from the survey and TB case notification 
in 2007/08, the magnitude of MDR-TB in Ethiopia was estimated to be 997 
cases, which includes 651 and 346 MDR-TB cases among newly diagnosed 
and re-treatment cases respectively. 
 
According to WHO 2008 report, in Ethiopia, 5,825 MDR-TB cases (4964 among 
newly diagnosed and 861 among previously treated TB cases) were estimates 
to have occurred in 2006 (WHO 2008a:12). In addition, based on the 
prevalence rate from the survey and TB case notification in 2007/08, the 
magnitude of MDR TB in Ethiopia was estimated to be 997 cases, which 
includes 651 and 346 MDR-TB cases among newly diagnosed and re-treatment 
cases respectively (FMOH 2009:2). 
 
2.4 HEALTH CARE SYSTEM OF ETHIOPIA IN RELATION TO TB  
 
The healthcare delivery system in Ethiopia emphasises primary healthcare 
(PHC), including preventive, promotive and basic curative services which 
involves prevention and control of diseases, including TB (FMOH 2007:14).  
 
The government of Ethiopia recently introduced a three-tier health care delivery 
system which is characterized by a first level of a Woreda/District health system 
comprising a primary hospital (with population coverage of 60,000-100,000 
people), health centres (1/15,000-25,000 population) and their satellite health 
posts (1/3,000-5,000 population) that are connected to each other by a referral 
system. A primary hospital, health centres and health posts form a primary 
health care unit (PHCU) with each health centre having five satellite health 
posts. The second tier is a general hospital with population coverage of 1-1.5 
million people; and the third tier a specialized hospital that covers population of 
3.5-5 million. Health management offices at different levels of the health sector 
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include the Federal Ministry of Health, Regional State Health Bureaus and 
Woreda Health Offices (one of the administrative unit below zonal level and 
above district/kebele level). Health Offices are responsible for financial and 
program planning, decision making in management and coordination, 
supervision, and quality assurance.  The FMOH and the Regional Health 
Bureaus (RHB) focus more on policy matters and technical support while 
Woreda Health Offices have basic roles of managing and coordinating the 
operation of a district health system under their jurisdiction. Regions and 
districts have RHBs and district health offices, respectively for the management 
of public health services at their levels. The devolution of power to regional 
governments has resulted in the shifting of decision making for public service 
deliveries from the centre to largely under the authority of the regions and down 
to the district level (FMOH 2010:4).  
 
A National TB Control Program (NTP) is in charge of all TB control activities and 
implementation guidelines following the DOTS principles. Task and 
responsibilities at Federal and Regional State Health Management Offices are 
clearly defined. However the MDR-TB program of the NTP needs to be tailored 
to the Regional State situation, based on local MDR-TB epidemiology, infra-
structure and taking into account cultural specifics. Therefore, the programmatic 
management of MDR-TB in Ethiopia is introduced in a stepwise manner, 
starting with a Green Light Committee approved pilot program in Addis Ababa. 
Nevertheless, a rapid expansion to the regions is foreseen and preparation is 
underway (FMOH 2009:3). 
 
2.5 TB PREVENTION AND CONTROL PROGRAM IN ETHIOPIA 
 
Tuberculosis prevention and control has been established from the time where 
TB has identified as one of the major public health problem in Ethiopia since 
about 5 decades. The effort to control tuberculosis began in the early 1960s 
with the establishment of TB centres and sanatoriums in three major urban 
areas in the country. These centres practically had not significant impact on 
reducing the burden of the disease in the country. The Central Office of the 
National Tuberculosis Control Programme was established in 1976. In 1992 a 
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standardised and well-organised TB programme, incorporating directly 
observed short course treatment, was implemented in a few pilot areas of the 
country (FMOH 2007:14). At present, tuberculosis control strategy in Ethiopia, 
relies on WHO recommended Stop TB Strategy and it has been implemented in 
the country since 2006 (FMOH 2009:1). 
 
In 2006, the World Health Organization (WHO) launched the Stop TB Strategy 
as the internationally-recommended approach to reducing the burden of TB in 
line with global targets set for 2015. The goal of the strategy is defined as: “To 
dramatically reduce the global burden of TB by 2015 in line with the Millennium 
Development Goals and the Stop TB Partnership targets.”   
 
It is of utmost importance that drug-resistant TB be prevented by rigorous 
adherence to the principles of the National Tuberculosis Control Programme 
(the DOTS strategy) and by patiently and consistently building partnerships with 
patients, their families and communities to cure TB at the first attempt (FMOH 
2009:3). Ethiopia has been implementing this WHO STOP-TB strategy since 
2006.  
 
In order to reach the national objectives and targets, the TB Control Program of 
Ethiopia is aligned with the globally recommended Stop TB Strategy which 
includes: 1) Early case detection, 2) Adequate chemotherapy, 3) Provision of 
comprehensive & standard patient care, 4) Enhanced case management,   5) 
Accurate Monitoring and Evaluation (M & E) of program performance, and  6) 
Community participation FMOH (2008:13). At peripheral level, TB is integrated 
within the general health care services. In a typical health facility, both 
laboratory personnel and outpatient department (OPD) staff are most of the 
time also in charge of other health activities. 
 
2.5.1 MDR-TB Prevention and Control in Ethiopia  
 
(FMOH 2009: 4) the government of Ethiopia adopted the five components of the 
DOTS Strategy as prevention and control of drug resistant TB: 1) Sustained 
political commitment by addressing the factors leading to the emergence of 
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MDR-TB, long-term investment of staff and resources, coordination of efforts 
between communities, local governments and international agencies, and a 
well-functioning DOTS programme. 2) Appropriate case-finding strategy 
including quality-assured culture and drug susceptibility testing (DST) in triage 
of patients into DST and the Drug-Resistant TB control programme in 
enhancing relationship with supranational TB reference laboratory. 3) 
Appropriate treatment strategies that use second-line drugs under proper case 
management conditions with rational treatment design (evidence-based), 
DOTS, monitoring and management of adverse effects, and properly trained 
human resources. 4) Uninterrupted supply of quality-assured second-line anti-
tuberculosis drugs. 5) Recording and reporting system designed for drug 
resistance-TB control programs that enable performance monitoring and 
evaluation of treatment outcomes. 
 
2.6 MDR-TB TREATMENT STRATEGIES IN ETHIOPIA 
 
Compared with therapy for drug susceptible tuberculosis, treatment of MDR-TB 
requires a longer duration, is considerably more complicated, expensive, and 
toxic, and treatment success rates are typically lower (Marahatta, SB. 
2010:122). 
 
General principles for designing a regimen for treatment of highly drug resistant 
TB are: 1) use of at least four drugs, whose effectiveness is highly likely or 
certain, 2) avoidance of drugs for which resistance crosses over, 3) elimination 
of drugs that are not safe for the patients, 4) inclusion of drugs from the 
following groups: a) first-line anti-TB drugs, b) injectable anti-TB agents c) 
fluoroquinolones, d) oral bacteriostatic second-line anti-TB drugs, and e) anti-
TB agents with un clear efficacy in a hierarchical order based on the potency, 
and 5) preparedness to monitor, prevent and manage adverse effects for each 
of drugs selected (Matteelli, A, Migliori, GB, Cirillo, D, Centis,  R, Girard, E, 
Raviglion,  M. 2007;5:857-871). 
 
 The TB Control Program in Ethiopia did not start managing MDR-TB cases with 
efficient second line protocols until 2009 (FMOH (2009:3).   
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The Ethiopian MDR-TB treatment strategy combines standardised and 
individualized treatment based on second line DST (kanamycin and Ofloxacin) 
in all confirmed MDR-TB patients. All MDR-TB suspects will be referred for line 
probe assay, followed by full first line-DST (FL-DST) and partial second line 
DST (SL-DST) once MDR-TB is confirmed. Whereas all known MDR-TB 
patients will have FL-DST and SL-DST performed simultaneously.  Line probe 
assay will assist in the decision to start the standard second line anti-TB 
treatment.  Standardised regimens will be given to all confirmed MDR-TB cases 
under daily DOT (at least one drug intake will be medically supervised per week 
daily). The initial phase will be at least six months, and then the continuation 
phase will be at least 12 months.  The total duration may be extended by 
clinicians according the findings of culture conversion. Treatment will be 
adjusted after receiving FL-and SL-DST result according to regimens (FMOH 
2009:47-48).  
 
In Ethiopia, the standard regimen for MDR-TB is: [Ethambutol- Pyrazinamide – 
Kanamycin (Amikacin)– Levofloxacin – Ethionamide – Cycloserine] for six 
months, and [Ethambutol – Pyrazinamide – Levofloxacin – Ethionamide – 
Cycloserine] for 12 months (FMOH 2009: 32-33) .  
 
Management of MDR-TB cases is coordinated by St. Peter TB Specialized 
Hospital in the city of Addis Ababa (FMOH 2009:5) which has the right clinical 
expertise and experience with managing the second line anti-TB drugs and their 
side effects. This Hospital functions as a national referral centre in case of 
severe side effects and as a centre of excellence and training during the scaling 
up to the regions. 
 
The All Africa Leprosy Rehabilitation and Training Center (ALERT) has recently 
begun contributing its share in treating MDR-TB patient since December 2011. 
The opening of the center has increased the number of MDR-TB treatment 
centers in Ethiopia to three. The other two are St. Peter‟s TB Specialized 
Hospital in Addis Ababa and Gonder University Hospital in Amhara Regional 
State. Besides, the Ministry has made preparations to open new MDR-TB 
diagnostic laboratories in Mekelle, Adama, Hawassa and Bahir Dar towns in 
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addition to existing two in Addis Ababa (http://www.ertagov.com/erta/erta-news-
archive/37-erta-tv-top-news-addis-ababa-ethiopia/1434-mdr-tb-diagnostic-labs-
treatment-centers-to-be-expanded-to-regional-towns-.html)  
 
2.7 RISK FACTORS FOR MDR-TB  
 
Drug resistant tuberculosis develops as a result of mismanagement of 
susceptible TB. The mismanagement may include inappropriate treatment 
regimens (e.g., a wrong choice of drugs, dosage and duration of treatment), 
programme factors (e.g., irregular supply, incompetent health personnel), and 
patient factors (e.g., poor adherence i.e. patients may feel better and halt their 
medication, mal-absorption) (FMOH 2011: 17).  In fact, it could be said that the 
occurrence of MDR-TB itself is an evidence of systematic failure of the 
community to tackle a curable diseases (Singh, JA, Upshur, R, and Padayatchi, 
N. 2007:0023).  Previous treatment, age group between 25-44 year and less 
than 65 years, TB/HIV co-infection, poor living conditions, poverty and 
malnutrition, homelessness, alcohol abuse, prisons and overcrowding are the 
risk factors for MDR-TB (Kliiman, K. 2009: 66). 
 
The increase in prevalence and incidence of MDR TB are caused by concurrent 
factors such as inadequate treatment regimens, poor case holding, suboptimal 
drug quality and transmission of resistant strains (WHO 2008b: 11). 
 
2.7.1 Previous history of tuberculosis treatment 
 
 Previous history of anti-tuberculosis treatment is the most widely reported risk 
factor for MDR-TB. Previously treated TB has strongest association with MDR-
TB in addition to the duration of previous TB treatment (Kiliman, K. 2009:64).  
Patients who received previous anti-tuberculosis treatment had a 4-fold 
increased odds of multidrug resistance (OR, 4.11 [CI, 2.77 to 6.08] (Kai, K, 
Altraja, A. 2009: 770;  Alistair, D,  Calver, Alecia, A, Falmer, Megan, M, Odelia, 
J,  Strauss, Elizabeth, M, Streicher, Madelene, H, Thelma, L, Mothusi, M, Paul, 
D,  Helden, V,  Robin, M, Warren, and Thomas C. Victor 2010: 268).  
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Prior exposure to anti-TB drugs is a well-established risk factor for drug 
resistance, as shown from surveys and surveillance systems worldwide (WHO 
2010:10).  Previously treated TB cases, however, are a heterogeneous group 
composed of relapse cases (that is, patients in whom TB has recurred after 
successful treatment), cases having failed one or more treatment regimens 
using first-line and/or second-line drugs, cases returning after treatment default, 
and others.   
 
The high proportion of MDR-TB among new TB cases could suggest suboptimal 
infection control, whilst the high percentage of MDR-TB among retreatment 
cases suggest poor case holding and follow-up or suboptimal use of TB 
regimens (Ködmön, C, Hollo, V, Huitric, E, Amato-Gauci, A, and Manissero, D. 
2010:4). 
 
In a study conducted in South Africa, nearly 30% of MDR-TB patients had no 
previous treatment for tuberculosis, and few had received more than one 
previous treatment regimen (Jason R. Andrews, N. Sarita Shah, Darren 
Weissman, Anthony P. Moll, Gerald Friedland, Neel R.Gandhi 2010:4).   
 
2.7.1.1 Types of previous TB treatment category 
 
In a study conducted in urban metropolis of Mumbai in Western India, 301/493 
(60%) of MDR-TB patients are among the first line treatment-failures (D‟souza 
et al 2009: 9). Failure of re-treatment regimens and chronic TB cases, relapse,  
return after default and  failure of first-line short course chemotherapy are 
among the risk factors for MDR-TB (FMOH 2009:15). C-Y Chiang et al (2010: 
418) the proportion of drug-resistant TB among previously treated TB cases 
consist of relapse, treatment after default, treatment after failure varied 
considerably in different settings depending on the prevalence of primary 
resistance. 
 
2.7.1.2 Previous TB treatment outcome 
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In the study done at Edendale Hospital in KwaZulu-Natal, Republic of South 
Africa showed that there is an association between treatment failure and any 
drug resistance of patients being re-treated for TB. TB treatment failure as 
outcome of previous treatment was associated with a 50-fold increase in risk of 
having MDR or XDR TB and was the most common re-treatment status among 
patients with MDR and XDR TB (Schreiber, Y, Herrera, A, Wilson, D, 
Wallengren, K, Draper, R, et al. 2009: 13: 1274–1280).  Another study 
conducted in the same country compared the MDR and  XDR-TB cases with 
drug susceptible TB controls, MDR and XDR-TB were strongly associated with 
a history of TB treatment failure (OR 51.7 [CI 6.6–403.7] (Andrews JR, Shah 
NS, Weissman D, Moll AP, Friedland G, et al.2010:4). 
 
A high proportion of MDRTB and poly-resistance, 41% (95/231) and 26% 
(59/231) respectively, was observed in a study conducted in India by D‟souza 
and his colleagues (2009) amongst the first line treatment-failures. A 
descriptive, case-series study conducted on MDR-TB patients registered for 
DOTS-Plus treatment at Bhim Hospital- the Rupandehi district hospital at 
Bhairahawa, Nepal  showed Out of the total MDR-TB study subjects, 4 (13%) 
had been marked as defaulters and as many as 4/5th of the patients had had an 
incomplete treatment of TB. The remaining 1/5th had treatment failure in spite of 
not missing a single dose of drug during the previous treatment (Pant, R, 
Pandey, KR, Joshi, M, Sharma, S, Pandey, T, Pandey, S 2009:90).  
 
2.7.2. TB/HIV Co-infection 
 
Recent global data have shown rising rates of drug-resistant TB in sub-Saharan 
Africa, the region also suffering from the world‟s highest burden of HIV/AIDS 
(WHO 2010: 6). MDR-TB is associated with HIV infection. The percentage of 
MDR-TB among HIV infected individuals was found to be three times higher 
(kiliman 2009:67).  Among 136 suspected cases of MDR-TB, HIV-infection was 
confirmed among 114 in South Africa (88%) (Scott K Heysell, Tania A Thomas, 
Neel R Gandhi, Anthony P Moll, François J Eksteen, Yacoob Coovadia, Lynette 
Roux, Palav Babaria, Umesh Lalloo, Gerald Friedland, Sarita Shah 2010:3).   
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Another study conducted at Tugela Ferry, KwaZulu-Natal province, South 
Africa, showed that among those ever tested for HIV infection, 90% of patients 
with MDR TB were co-infected with HIV (Gandhi, Shah, Andrews, et 
al.2010:82).  But in a systematic review of studies that assessed HIV infection 
as a risk factor for MDR-TB (Suchindran, S, Brouwer, ES, Van Rie, A. 2009:4), 
association between MDR-TB and HIV or acquired MDR-TB and HIV was not 
demonstrated, but there was suggestion that HIV infection is associated with 
primary MDR-TB.  However, based on the current data, HIV-positive TB 
patients in three Eastern European countries (Estonia, Latvia and the Republic 
of Moldova) appear to be more at risk of harbouring MDR-TB strains.  
 
In Lithuania, where drug resistance data could not be disaggregated by HIV-
negative and unknown HIV status, HIV-positive TB patients had a 8.4 (95% CI: 
2.7–28.2) times higher odds of harbouring MDR-TB strains than TB patients for 
whom HIV status was unknown, indicating a possible association of the two 
epidemics (WHO 2010:14). According to current hypotheses HIV increases the 
chances of transmission of MDR-TB rather than leading to an inadequate 
treatment (WHO 2008).   However the study conducted in Nepal by Pant, R, 
Pandey, KR, Joshi, M, Sharma, S, Pandey, T, Pandey, S (2009:91) showed that 
only 2 out of the 31 MDR-TB patients tested positive for HIV. The other 29 had 
a negative test indicating HIV positive status and MDR may be events 
independent of each other.   
 
2.7.3 Age and MDR-TB 
 
In a surveillance data collected from 13 countries of Central and Eastern 
Europe, the frequency of MDR-TB was much higher in all age groups compared 
with the rest of the countries (all high-income) and peaked in young adulthood. 
In the high-income non-Central and Eastern Europe group, frequency of MDR-
TB declined linearly with age-group (p<0.05). This pattern suggests that in the 
countries of the former Soviet Union, where many MDR-TB cases are of local 
origin, the MDR-TB epidemic is a relatively recent phenomenon and bears the 
highest toll on young adults (WHO 2010:4).   
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Younger age is known to be the significant contributor for development of MDR-
TB (W. S. Law et al. 2008:1065).  Contrary to this, the study conducted in South 
Africa showed that age was not a significant risk factor, it was found that MDR-
TB was cultured from the blood in patients as young as 8 years and as old as 
62 years (Scott et al. 2010:3).  
 
D‟souza et al (2009: 9) reported a significantly higher proportion of failures 
(MDR cases) in the age group of 36–55 years as compared to those whose 
strains were sensitive/mono-resistant (p < 0.022). A significantly higher number 
of treatment-failures were MDR as compared to the new cases (p = 0.0). 
 
2.7.4 Sex and MDR-TB 
 
According to WHO (2010) drug resistance surveillance report, among 38 
countries and 3 territories the odds ratio of harbouring MDR-TB strains for 
female TB cases compared with male TB cases was 1.1 (95% CI: 0.9–1.4), 
showing no overall association between MDR-TB and sex of the patient.   In 
South Africa, although a higher number of male than female MDR-TB cases 
were reported (4826 vs 4615 cases, respectively), data from a total of 81,794 
TB patients with known sex (95% of all patients) indicates that female TB cases 
have a 1.2 times higher odds of harbouring MDR-TB strains than male TB 
cases. Data from Australia, the Netherlands and the United States of America 
also show a higher risk of MDR-TB in female patients (WHO 2010:12).  
 
In a study conducted in Peru among 673 patients, more than half of diagnosed 
and confirmed (60.8%) MDR-TB were male which shows that gender is a risk 
factor for the development of MDR-TB (Molly F. Franke,  Sasha C. Appleton, 
Jaime Bayona , Fernando Arteaga,  Eda Palacios, Karim Llaro, Sonya S. Shin, 
Mercedes C. Becerra, Megan B. Murray, and Carole D. Mitnick 2008:4). 
 
In a systematic review conducted  by A Faustini, A J Hall, C A Perucci 
(2006:161) there was  a stronger association of being a male sex as a risk 
factor for MDR-TB  (OR 1.54; 95% CI 1.31 to 1.82) in the eight studies carried 
out in Western Europe and heterogeneity between studies were very low 
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(p=0.956).  Men were at lower risk of MDR-TB in the three studies carried out in 
the former USSR (OR 0.86; 95% CI 0.43 to 1.71) with a high heterogeneity 
between studies (x2=6.53; p=0.04). 
 
2.7.5 Poor TB Treatment Adherence 
 
Non-adherence to prescribed treatment is often underestimated. Poor 
compliance with treatment is also an important factor in the development of 
acquired drug resistance.  Poor adherence were related to age differences as 
younger patients are often occupied by study, work or other activities on a daily 
basis, in contrast with the more sedentary lifestyle post-retirement age (W. S. 
Law et al. 2008: 1066). 1/5th TB patients had developed treatment failure as an 
outcome of TB treatment in Nepal in spite of not missing a single dose of drug 
during the previous treatment (Pant, R, Pandey, KR, Joshi, M, Sharma, S, 
Pandey, T, Pandey, S 2009:90), showing that poor or good adherence to 
therapy is not linked to the emerging problem of MDR-TB. 
 
2.7.6 Site of TB Involvement 
 
In a study conducted in Hong Kong, the vast majority of MDR-TB cases 
suffered from pulmonary TB (PTB) (98%), and only 2% presented with extra-
pulmonary TB (EPTB) alone (W. S. Law et al. 2008: 1066).  On the contrary, a 
study conducted in South Africa showed that approximately one quarter of drug 
resistant TB patients were diagnosed with extra-pulmonary TB in addition to 
pulmonary TB (Andrews et al.2010:3).  Another study conducted in Tomsk, 
Russian Federation, discloses that sputum-smear positivity was significantly 
associated with MDR-TB (IY Gelmanova, S Keshavjee, VT Golubchikova, VI 
Berezina,  AK Strelis, GV Yanova, S Atwood & M Murray 2007:705). 
 
 
 
 
 
 
~ 25 ~ 
 
CHAPTER 3 
 
Research Design and Methodology 
 
3.1 INTRODUCTION 
 
Research methodology is the approach or the design that is followed by a 
researcher to answer a particular research question. As described by Burns and 
Grove (2005:211), research methodology is the strategy that will be applied in a 
process that begins with the identification of the research problem and ends 
with plan of data collection. This research was done using a quantitative, 
descriptive and comparative cross-sectional research design. Data were 
collected using checklist which was designed to align with the national TB 
registration log-book in order to collect the study variables through medical 
record reviews.  
 
This section covers the design of the study, how the sample was selected, the 
setting where the study was conducted, the study population, inclusion and 
exclusion criteria used during the study. 
 
3.2 STUDY DESIGN 
 
Polit and beck (2007:49) defines the study design as the overall plan for 
obtaining answers to the questions being studied and for handling some of the 
difficulties encountered during the research process.  A research design is a 
blueprint for conducting the study that maximizes control over factors that could 
interfere with the validity of the findings (Burns & Grove 2005:211).  A research 
design is a plan indicating how the study is going to be carried out. It is a plan 
guide for providing sound answers to a research questions. The study design 
guides what type of observations, and which measurement instrument will be 
adopted and when to conduct the data collection (Stommel & Wills 2004:32-34).  
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The research design followed for this study is comparative cross-sectional study 
design. The objective of the study was to determine the risk factors contributing 
for the occurrence of MDR-TB in Addis Ababa, Ethiopia.  
 
3.2.1 Quantitative 
 
In quantitative research, evidence is gathered according to a specified plan, 
using formal instruments to collect the needed information (Somekh & Lewin 
2005:215).   Max Mmuya (2007:80) defined quantitative research as “a formal, 
objective, systematic process in which numerical data are utilized to obtain 
information about the world”. 
 
This study reviewed medical records of MDR-TB patients and compared their 
information with non-MDR-TB patients to determine the risk factors for MDR-
TB.  
 
3.2.2 Descriptive study 
 
Polit and Beck (2007:193) descriptive studies is to observe, describe, and 
document aspects of a situation as it naturally occurs and sometimes to serve 
as a starting point for hypothesis generation or theory development. It is the 
study which seeks to document the characteristics, prevalence, intensity, or full 
nature of phenomena. Descriptive designs help to identify problems in current 
practice with a view to improve practice outcomes (Burns and Grove 2005:248). 
The study determines differences between the two groups (MDR-TB and non 
MDR-TB patients) and provides detailed analysis of the risk factors for 
emerging problem of MDR-TB in Addis Ababa. 
 
3.2.3 Cross-sectional Research Design 
 
 A study design in which data are collected at one particular point in time is 
called a cross-sectional research design (Polit & Beck 2008: 751). As described 
by Stommel and Wills (2004:159) a cross-sectional study is a study which 
collects information at a single point in time.  A cross-sectional research design 
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assesses and describes the prevalence of the outcome or the extent of the 
exposure of a population to a predetermined phenomenon. The sample in a 
cross-sectional study is assembled randomly without any reference to exposure 
or outcome. The researcher then compares the outcome with the exposure, and 
tries to determine whether there is a difference in the prevalence of the outcome 
when it is compared to the exposure of the population (Morroni & Myer 2007: 
85).  
 
According to Burns and Grove (2005:236), cross-sectional study designs 
examine participants simultaneously, irrespective of their stage of development 
but with an aim to describe differences in phenomena across stages. Data is 
collected at a point in time but with different study participants, as opposed to 
different points in time for the same participant (Brink 2007:10). 
 
3.2.4 Comparative studies  
 
Comparative studies are used to examine existing differences between 
variables in two or more groups in their natural uncontrolled setting, and the 
results are not usually generalisable (Burns & Grove 2005:730).  
 
3.3. SAMPLING 
 
Sampling is a process of selecting a portion of population, which is an entire 
aggregate of cause (Polit and Beck 2008:362). Sampling involves a process of 
selecting a sub-set of a population which represents the entire population in 
order   to obtain characteristics of a particular phenomenon. A sample is the 
sub-set of cases or observations drawn from a population, who fulfilled the 
eligibility criteria participated in the study. There are two methods of sampling; 
one yields probability sampling in which the probability of selection relies on 
random selection process and the other is the non-probability sampling where 
sample selection does not follow random selection procedures (Stommel & 
Wills 2004:297-300).  
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The researcher used a systematic random sampling method to select non 
MDR-TB patients registered in the 26 public health centres in Addis Ababa 
between January 2008 and December 2011 and fulfilling the selection criteria 
while all MDR patients seen in the 26 public health centres were included in the 
study. A total of 113 MDR-TB patients were registered in these 26 public health 
centers during the period. The number of non-MDR patients sampled from each 
health centre corresponded with TB case load and number of MDR-TB 
contributed from the site.  TB registers were used as data source. From the 
registers found in each health center, the ID numbers assigned to each patient 
seen between January 2008 and December 2011 were listed serially and every 
nth non-MDR patient was selected for review until the required number of 
sample from the site is fulfilled. 
 
This means that each individual in the non-MDR TB population followed at the 
26 public health centers had fairly equal chance of being selected for the 
sample (Joubert & Katzenllenbogen 2007: 95-96).  
 
3.4 STUDY POPULATION 
 
When conducting a study, it is important to define clearly the group about which 
we want to gather information and draw conclusions. This group called the 
study (target) population should be clearly defined in respect of person, place 
and time as well as other factors relevant to the study (Joubert, et al 2007:94).  
Population is the collection of persons, objects or things that fulfil certain criteria 
set by the researcher for inclusion in the study where the researcher has a 
reasonable access (Burns & Grove 2005:40).  
 
 In this study, the study population comprised all TB patients confirmed to be 
MDR and non MDR-TB registered in 26 health centres in Addis Ababa from 
January 2008 to December 2011 meeting the following inclusion criteria:  
 
3.4.1 Inclusion criteria 
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 MDR-TB confirmed by culture and drug sensitivity test. 
 Any age of confirmed and registered to be MDR-TB and non MDR-TB 
among the health centers in Addis Ababa. 
 Registered between January 2008 to December 2011 for both MDR-TB 
and non MDR-TB 
 Either AFB, clinical or radiological evidence of sensitive tuberculosis for 
non MDR-TB. 
 
3.4.2 Exclusion criteria 
 
 Patients whose registries were not found in the health center or 
information on the register was incomplete for the variables of interest.  
 Being XDR-TB patient. 
 
3.5 SAMPLE SIZE 
 
Saks and Allsop (2007:158) state that the larger the sample size, the smaller 
the error will be in estimating the characteristics of the whole population, but the 
more it will cost to administer a survey and analyse the data. The sample size is 
dependent on the accuracy required and the likely variation of the population 
characteristics being investigated. 
 
The number of MDR-TB and non MDR-TB registered in the 26 public health 
centres in Addis Ababa between January 2008 and December 2011 and 
fulfilling the selection criteria were selected using systematic sampling method. 
Risk of exposure to MDR-TB among newly confirmed TB patients was taken as 
an indicator variable in order to estimate the minimum number of cases that 
need to be sampled for the study.  According to the Federal MOH of Ethiopia, 
the risk of MDR-TB among newly confirmed TB patients is nearly 2% compared 
to 12% among re-treated TB patients (FMOH 2009:3).   
 
 A Fleiss with Continuity Correction sample size calculation formula using Open 
Epi version 2.3 for windows were used to calculate the sample size.  A marginal 
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error of 3%, 80% study power, 95% confidence limit and a ratio of exposed 
(MDR) to un-exposed (non MDR) of 1:3 were assumed.   Accordingly, a total of 
400 study participants (100 MDR-TB and 300 non MDR-TB) are assumed to be 
included in this study. 10% of the samples were added to cater for incomplete 
data making the total sample size of 439 (113 MDR-TB and 326 non MDR-TB).  
 
3.6 RESEARCH SETTING 
 
The study was conducted in Addis Ababa, the capital city of Ethiopia. It is 
divided into ten sub cities and 110 woredas (the lowest administrative units).  
During the data collection of this study only 26 public health centres were 
providing MDR-TB treatment and follow up services whose conditions are 
stable after refereed from St. Peter specialised hospital in Addis Ababa. 
 
3.7 DATA COLLECTION 
 
The process by which values are obtained for the characteristics of individuals 
being studied (Joubert, et al 2007: 106). Data collection is the gathering of all 
the pertinent information necessary to answer a particular research question or 
hypothesis (Stommel & Wills 2004:363).   
 
The data collection instrument was designed to abstract data from patient 
record - the TB registers. Data abstraction instrument was piloted in a selected 
health centre before the actual data collection took place. Data abstractors were 
focal TB nurses in each of the 26 public health center who are familiar with TB 
registers. They were trained to abstract data and the principal investigator did 
the quality control check. A total of two days training was given for supervisors 
and data collectors. The quality of the data was ensured throughout instrument 
development, data entry and analysis.  
 
3.7.1 Research instrument 
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A research instrument is used to measure a variable of interest (Bowling 
2002:144). (Joubert, et al 2007: 106) review of records much potentially useful 
health relate information is collected routinely as part of patient care, for 
example, for each patient who visits clinic. A research instrument is used to 
measure a variable of interest (Bowling 2002:144).  
 
The abstraction form was developed based on the Ethiopian standardized 
national TB register and after review of literature and consultation of TB focal 
persons and programme managers. The checklist comprised the following 
sections: 
 
Section I: Socio-demographic characteristics 
Section II: TB treatment status, category and outcome  
Section III: TB treatment adherence  
Section IV:  TB/HIV co-infection status 
 
3.8 DATA ANALYSIS 
 
Polit and Beck (2008:507) identified the purpose of data analysis is to organize, 
provide structure to, and elicit meaning from research data.  Trochim (2006:101) 
explained that in most social research, data analysis involves three major steps, 
namely cleaning and organising the data for analysis, describing the data, and 
testing hypotheses and models. De Vos, et al (2007:218) describe data analysis 
as the process of categorizing, putting into order, manipulating and ultimately 
summarizing data in order to be able to answer the original research questions. 
  
The data were coded and entered in to Epi-Info (version 3.5) and exported to 
SPSS version 16.0. Odds ratio, Chi-square test, and logistic regression were 
calculated for inferential statistics and tables, graphs, charts, and percentages 
were used for descriptive statistics    
 
3.9 VALIDITY AND RELIABILITY 
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Validity and reliability are concerned with the quality of the data and 
appropriateness of the methods used in carrying out the study. 
 
3.9.1 Validity of research instrument 
 
Polit and Beck (2007:196) defines Validity-the soundness of the study evidence-
that is, whether the findings are unbiased, cogent and well grounded. It is 
whether there is evidence to support the assertion that the methods are really 
measuring the abstract concept that they purport to measure. Validity refers to 
the instrument‟s accuracy to measure the characteristics or attributes that it 
intends to measure (Stommel & Wills 2004:222). 
 
To maintain the validity of the study, conceptual and operational definitions of 
terms were used according to the objective of the study.  Records that meet 
eligibility and exclusion criteria based on clinical and laboratory results 
confirmed diagnosis will be selected.  Pre-tested data abstraction forms were 
used.  The data was stratified for age and gender and multivariate analysis 
were employed during the analysis.  Consultation with medical officers and 
nurses providing medical service for TB patients were done to measure the 
construct domain of the study to ensure instruments validity.  
 
3.9.2 Reliability of research instrument 
 
Reliability refers to the accuracy and consistency of information obtained in the 
study (Polit and Beck 2008:196). Reliability is the reproducibility and 
consistency of a measurement instrument‟s ability to produce results that are 
consistent across persons and time (Stommel & Wills 2004:209). To maintain 
the reliability of the study, careful training, development of a clearly defined 
standardized format after reviewing the literature, pre testing of the abstraction 
instrument and consulting experts in the field were designed and a small 
number of research assistants were used to enhance the accuracy of observer 
ratings and classifications. Only the researcher was responsible for cleaning 
abstracted data during conducting of the actual research and by so doing 
increased the chances of consistency collected data.   
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3.10 ETHICAL CONSIDERATIONS  
 
In order to ensure the rights of study participants are not violated, researchers 
have to adhere to strict ethical standards (Burns & Grove 2005:176). The 
Principle of Beneficence‟ requires the researcher to “do good and above all, do 
no harm” (Burns & Grove 2005:180).  The primary ethical principles on which 
standards of ethical conduct in research are based: beneficence, respect for 
human dignity and justice (Polit & Beck 2008: 170-174).  
 
3.10.1 Protection of human rights: 
 
The human rights that require protection in research are: 
o Right to self determination 
o Right to privacy  
o Right to anonymity and confidentiality 
o Right to fair treatment 
o Protection from harm and discomfort (Burns and Grove 1999:196)  
This study involves review of patient records.  It did not involve direct contact 
with human beings thus no potential for inconveniencing patients by providing 
personal information.  Nonetheless, all the necessary ethical precautions to 
protect privacy and confidentiality of personal information have been observed.  
Names and addresses of patients were not included in the abstracted 
information (de-identification).  Data was kept in locked cabinets and password 
protected computers during data processing and analysis. 
3.10.2 Informed consent: 
 
Informed consent is not applicable for this study because the study did not have 
direct interaction with patients as it used secondary data.  
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3.10.3 Autonomy: 
 
In this study, data was abstracted from medical records and hence there is no 
direct interaction with the patients.  Authorities act on behalf of the patients, 
autonomy of the participant were maintained through approval by facility 
authorities for undertaking the study.  Authorities at the study sites were asked 
to specify their own restriction on the access to and use of their data. 
 
3.10.4 Confidentiality and anonymity: 
 
For this study, patient personal identifiers (such as name and address) were 
removed from abstraction to ensure anonymity of data while maintaining the 
integrity of the medical records.  The collected data was stored in locked 
cabinets and secured databases. The access to the abstracted data was limited 
to the researcher and those who were involved in analysis of the data were 
limited. The researcher also informed all the facility authorities that although the 
data obtained from the health records might be reported in scientific journals, no 
information would ever be disclosed that will enable any third party to identify 
them as participants in the research. 
 
3.10.5 Beneficence: 
 
The researcher did not directly interact with the patients. The facility authorities 
were informed that the benefits of this study outcome outweigh the risks to the 
study participants by contributing to the existing body of scientific knowledge by 
identifying the risk factor for lethal diseases of MDR-TB.  
 
3.10.6 Justice: 
 
 Risk/benefit ratio-there was no risks of exposing the respondents to discomfort 
or harm as there is no direct interaction with the patients. But potential benefit of 
the study is to contribute the existing body of knowledge about MDR-TB in 
determining the risk factor. 
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3.10.7 Rights of institutions where the research is based: 
 
Prior to conducting the study, ethical clearance was sought from the University 
of South Africa (UNISA) postgraduate research and ethics committee. 
Authorised cooperation letter were written from UNISA regional learning centre 
to Addis Ababa City Administration Health Bureau (AACAHB). A request for 
permission letter having detailed explanation of the research itself, the reasons 
for the research and kind of research that would be conducted in the facility 
were approved by AACAHB and the authorities at the study sites. Authorities at 
the study site were assured that any information that the researcher will come 
across during the conduct of the research will not be divulged to any interest 
groups that could jeopardize the patient‟s welfare in society and the concerned 
institution.  The researcher abided by the guideline of the institutions, which has 
the right to terminate the study if the safety and confidentiality of patients‟ 
records are compromised.   
 
3.10.8 Scientific integrity on the part of the researcher: 
 
To maintain scientific integrity and eliminate the possibility of scientific 
misconduct and plagiarism, the researcher strictly adhered to ethical and 
appropriate use of scientific knowledge by refrain from falsifying or fabricating 
primary and secondary data.  The information obtained from patient records‟ 
were recorded as such. Clear reference was given to the respective source 
when citing ideas, words, processes, findings and results obtained by other 
authors, and important results which are contrary to the researcher‟s results and 
conclusions. 
 
3.11 CONCLUSION  
 
This chapter described the research design and methodology, including the 
population, data collection and analysis, validity and reliability, and ethical 
considerations. Chapter 4 presents the data analysis and interpretation. 
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CHAPTER 4 
 
Analysis and discussion of the research findings 
 
4.1 INTRODUCTION  
 
In the previous chapter, the research design and methodology was described. 
This chapter presents the results with the aid of percentages, tables and 
graphs. The purpose of the study was to investigate the risk factors for MDR-TB 
in Addis Ababa, Ethiopia in order to add to the paucity of knowledge in this area 
of public health.  
 
The specific objectives of the study were to:  
o To determine the socio-demographic factors associated with MDR-TB 
among patients in Addis Ababa. 
o To determine if non adherence to treatment is associated with 
development MDR-TB. 
o To determine the types of TB treatment categories and treatment 
outcomes associated with MDR-TB.  
o To determine the association of HIV/AIDS and MDR-TB in Addis Ababa.  
 
4.3 DATA MANAGEMENT AND ANALYSIS 
 
Medical record of 439 patients was analysed - 113 MDR-TB cases and 326 non 
MDR-TB patients. All MDR-TB patients registered at 26 public health centres in 
Addis Ababa between January 2008 and December 2011 were included and 
the number of matching non MDR-TB patients from each health centre was 
decided using systematic random sampling technique. The data was at all times 
kept safely and stored in a place to which no one other than the researcher had 
access, and the data was saved and protected on by a secret password. 
 
MDR-TB and non MDR-TB patients were compared on key socio-demographic 
and patient related factors (potential risk factors) for drug resistance. Initial 
descriptive analyses of all variables of interest were performed. Statistical 
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inference was made at 95% confidence limit. Univariate analysis was carried 
out in order to identify potential risk factors associated with drug resistance in 
TB treatment. The strength and magnitude of associations were estimated for 
each variable from the corresponding univariate model and expressed in terms 
of an odds ratio. Subsequently, multiple regression analysis was carried out 
with the set of variables that showed strong association in the univariate model. 
Maximum effort was used to include the potential risk factors for drug resistance 
in the model with multivariate setting.  
 
A statistician assisted in data entry using Epi Info version 3.5 and analysis by 
exporting data to the Statistical Package for the Social Science (SPSS), version 
16.0, and micro-computer program. The data analysis was discussed in 
accordance with the sections of the checklist. 
 
4.4 RESEARCH RESULTS  
 
4.4.1 Socio-demographic characteristics  
 
This section covers description of study population‟s background by characters 
such age, gender, and geographical location of residence. 
 
Table 4.1: Socio-demographic data of the patients (n=439) 
Characteristics 
 
MDR-TB 
patients 
(n= 113) 
non MDR-TB 
patients  
   (n= 326) 
Crude OR  
(95% CI) 
p-value 
  Gender:  
             Male 
Female 
 
73 (65%) 
40 (35%) 
 
166 (51%)  
160 (49%)   
 
1.8 (1.13-2.74) 
 
0.012 
        Age:  
5-14 
15-24 
25-34 
35-44 
45-54 
55-64 
≥65 
 
2 (2%) 
36 (32%) 
36 (32%) 
16 (14%) 
11 (10%) 
7 (6%) 
5 (4%) 
 
15 (5%) 
99 (31%) 
100 (31%) 
54 (17%) 
29 (9%) 
16 (5%) 
11 (3%) 
 
0.3 (0.05-1.801 
0.8 (0.26-2.46) 
0.79 (0.25-0.4) 
0.65(0.197-2.2) 
0.8(0.236-2.96) 
0.963 (0.24-3.829) 
1.00 
 
0.293 
0.800 
0.792 
0.652 
0.834 
0.0963 
Geographical location:  
Urban 
Rural 
 
103 (91%) 
10(9%) 
 
258(79%) 
68 (21%)     
 
2.7 (1.35-5) 
1.00 
 
0.005 
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4.4.1.1: Sex distribution  
 
Of the total, 54% (n=239) were males and 46% (n=200) were females. Among 
the males, 65% (n=73) were MDR-TB patients and 51% (166) were non MDR-
TB patients (OR: 1.8; 95% CI: 1.13-2.74), while of the females 35% (n=40) were 
MDR-TB patients and 49% (160) females were non MDR-TB patients (OR: 
0.56; 95% CI: 0.36-0.86). Multivariate analysis demonstrated that male gender 
is associated with acquiring MDR-TB (OR 2; 95% CI 1.035-5). 
 
4.4.1.2: Age distribution  
 
The youngest TB subject was 5 years old, while the oldest TB subject was 77 
years old. The median age was 29 years (SD of 14). More than 60% of both 
MDR and non-MDR patients were 15-34 years old.  There was no statistically 
significant age difference between MDR and non-MDR patients.  
 
4.4.1.3: Geographical location of residence  
 
362 (82.2%) were urban residents whereas 78 (17.8%) came from rural 
geographical locations. Urban residents made up 91% (103) of the MDR-TB 
patients and 79% (259) among non MDR-TB patients (OR: 2.75; 95% CI: 1.35-
5.00). Similarly, 9% (10) of the MDR-TB and 21% (68) of the non MDR-TB 
patients were coming from rural part of the country. The proportion of urban 
resident MDR-TB patient seems to be much greater than those of rural 
residents. But, during multivariate analysis urban residence is not associated 
with acquiring MDR-TB (OR=1.6; 95% CI:  0.5-5). 
 
4.4.2: TB treatment adherence status  
 
4.4.2.1: Missed a dose of anti-TB drugs during intensive phase of previous 
treatment  
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Of 99 MDR-TB and 28 non MDR-TB patients who had history of previous TB 
treatment, 11% (11) of MDR-TB and 18% (5) of non MDR-TB patients 
respectively missed dose of TB during intensive phase.  16% (16) of MDR-TB 
cases and 36% (10) of non MDR-TB patients didn‟t miss anti-TB treatment 
during intensive phase of previous treatment.  But information on missed 
medication during intensive TB treatment period was unknown by far more 
MDR-TB patients 73% (72) compared to non-MDR TB patients 46% (13).  
 
4.4.2.2: Previous TB treatment adherence status of the patient  
 
 91% (10) of the MDR-TB and 20% (1) of the non MDR-TB patients missed to 
pick ≥20% of their monthly dose (X2 test, p=0.005). 9% (1) of MDR-TB and 80% 
(4) non MDR-TB patients missed <20% of their monthly medications.  There is 
significant association between acquiring MDR-TB and poor adherence to TB 
treatment. 
 
4.4.3: TB treatment status, category and outcome  
 
4.4.3.1: Previous history of TB treatment  
 
Table 4.2: Previous history of TB treatment status of MDR-TB (n=113) and 
non MDR-TB (n=326) 
Characteristics 
 
MDR-TB 
patients 
(n=113) 
Drug 
sensitive TB 
   (n=326) 
  Crude OR  
  (95% CI) 
p-value 
Previous history of TB 
treatment: 
Yes 
No 
 
 
99 (88%) 
14 (12%) 
 
 
28 (9%) 
298 (91%) 
 
 
 75 (38-148 ) 
 1.00 
 
 
0.00 
 
Among the MDR-TB patients, 88% (99) have previously been treated for TB in 
comparison to 9% (28) of the non-MDR group (OR 75; 95% CI 38-148). Over 
90% (298) of the non-MDR group had no history of previous TB treatment 
compared to 12% (14) of the MDR group (OR 0.013; 95% CI 0.007-0.026).  
Similarly, during multivariate analysis strong association is shown between 
previous history of TB treatment and risk of becoming ill with MDR-TB (OR 112; 
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95% CI 47-267).The finding of this study showed that those with history of 
previous TB treatment were 112 times more likely to become ill with MDR-TB in 
comparison to those who had no previous history of TB treatment. 
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Figure 4.1 History of previous TB treatment in MDR-TB (n=113) and non 
MDR-TB (n=326) 
 
4.4.3.2: Previous category of TB treatment  
 
Table 4.3: TB treatment category, frequency and outcome among those 
previously treated MDR-TB (n=99) and non MDR-TB (n=28) 
Characteristics 
 
MDR-TB 
patients 
(n=99) 
Drug 
sensitive TB 
   (n=28) 
Crude OR  
(95% CI) 
p-value 
Previous category of TB 
treatment:  
      Failure 
      Relapse 
      Return after default 
    Failure after re-treatment 
      Not known 
 
 
19 (19%) 
6 (6%) 
2 (2%) 
70 (70%) 
2 (2%) 
 
 
6 (20%) 
15 (54%) 
1(4%) 
5 (18%) 
1 (4%) 
 
 
3.167 (0.36-27) 
0.4 (.05-3.5) 
2 (0.09-44) 
17 (2-158) 
1.00 
 
 
0.297 
0.409 
0.661 
0.011 
 
Number of times the 
patient used anti-TB drugs:  
       ≥2 times 
Once  
 
 
89 (90%) 
10 (10%) 
 
 
13 (46%) 
15 (54%) 
 
 
10 (3.8-27) 
1.00 
 
 
 
0.000 
Outcome of previous 
treatment: 
Failure 
Defaulted 
Treatment completed 
 
 
90 (91%) 
6 (6%) 
3 (3%) 
 
 
6 (21%) 
17 (61%) 
5 (18%) 
 
 
36 (7-187) 
0.7 (0.13-3.7) 
1.00 
 
 
0.00 
0.683 
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 Failure after re-treatment constitutes 70% (70) among MDR-TB patients and 
18% (5) for non MDR-TB patients respectively (OR 17; 95% CI: 2-158).  Failure 
of first time TB treatment constitutes 19% (19) for MDR-TB and 20% (6) for non 
MDR-T B patients, 6% (6) of MDR-TB and 54% (15) of non MDR-TB patients 
were categorised as relapse, and return after default constitutes 2% (2) of 
MDR-TB and 4% (1) of non MDR-TB. Result of multivariate analysis showed, 
TB treatment category of failure after re-treatment is strongly associated with 
becoming ill with MDR-TB (OR 31; 95% CI11-63). 
 
This result shows that those patients who failed after re-treated for TB were 31 
fold at risk of becoming ill with MDR-TB in comparison to other category of TB 
treatment.  
 
4.4.3.3: Number of times treated for TB  
 
Of all MDR-TB patients‟ 90% (89) MDR-TB patients were treated more than 
twice for tuberculosis in comparison to 46% (13) of non MDR-TB patients (OR 
10; 95%CI 3.8-27). Multivariate analysis of the variable showed, those who 
received TB treatment more than two times were higher risk of becoming ill with 
MDR-TB (OR=1.7; 95% CI 1.03-34). From this result, frequency of TB treatment 
was strongly associated with developing MDR-TB.  
 
4.4.3.4: Previous TB treatment outcome  
 
Of all MDR-TB patients 91% (90) had failure as TB treatment outcome 
compared to 21% (6) among non MDR-TB patients (OR 36; 95% CI 7-187). The 
remaining 6% (6) of the MDR and 61% (17) of the non MDR-TB patients had 
defaulted from previous treatment (OR 0.7; 95% CI 0.13-3.7). During 
multivariate analysis strong association is demonstrated between TB treatment 
outcome of failure and further risk of acquiring MDR-TB (OR 29; 95% CI 1.93-
6). From this finding there is strong association between TB treatment failure 
and risk of becoming ill with MDR-TB. 
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Figure 4.2 TB treatment outcome in previously treated MDR-TB (n=99) and 
non MDR-TB (n=28)  
 
4.4.3.5: Site of TB involvement  
 
Table 4.4: Site of TB involvement among MDR-TB (n=113) and non MDR-
TB (n=326)  
Characteristics 
 
MDR-TB 
patients 
(n=113) 
Drug 
sensitive TB 
   (n=326) 
Crude OR  
(95% CI) 
p-value 
Site of TB involvement:  
Pulmonary  
Extra-pulmonary 
 
100(88.5%) 
13 (11.5%) 
 
216 (66%) 
110 (34%)  
 
3.9 (2-7.3) 
1.00 
 
0.00 
Result of Acid Fast Bacilli 
(AFB) smear for current TB 
treatment: 
Positive  
Negative 
 
 
 
89 (79%) 
24 (21%) 
 
 
 
132 (40.5%) 
194 (59.5%)  
 
 
 
5.5 (3.3-9) 
1.00 
 
 
 
0.00 
 
Big majority of TB infections, 88.5% (100), were pulmonary TB among the 
MDR-TB patients compared to 66% (216) among non MDR-TB (OR 4; 95% CI 
2-7.3). The sites involved in 11.5% (13) of MDR-TB were extra pulmonary 
compared to 34% (110) among non MDR-TB patients (OR 0.26; 95% CI 0.14-
0.5). Significant association between becoming ill with MDR-TB and pulmonary 
involvement of TB were demonstrated during multivariate analysis (OR 2; 95% 
CI 6-23).  
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Figure 4.3 Site of TB involvement for MDR-TB (n=113) and non MDR-TB 
(n=326) patients 
 
4.4.3.6: Result of Acid Fast Bacilli (AFB) smear  
 
From this study 79% (89) of MDR-TB and 40.5% (132) non MDR-TB were 
smear positives (OR 5.5; 95% CI: 3.3-9), 21% (24) of MDR-TB and 59.5% (194) 
of the non MDR-TB were smear negative pulmonary TB.  Significant association 
between becoming ill with MDR-TB and positive AFB smear were demonstrated 
during multivariate analysis (OR 8; 95% CI 3.5-19). From this result of study, 
MDR-TB patients are 8 times more likely present with smear positive in 
comparison to non MDR-TB patients.  
 
4.4.4: HIV status of the MDR-TB and non MDR-TB patients 
 
Table 4.5: HIV status of study participants in MDR-TB (n=113) and non 
MDR-TB (n=326) 
Characteristics 
 
MDR-TB 
patients 
(n= 113) 
Non MDR-TB   
(n= 326) 
Crude OR  
(95% CI) 
p-value 
Result of HIV test: 
Positive 
Negative 
 
54 (48%) 
59 (52%) 
 
85 (26%)  
241 (74%)  
 
3 (2-4) 
1.00 
 
0.00 
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4.4.4.1: TB/HIV co-infection  
 
Almost half, 48% (54) of MDR-TB and 26% (85) of non MDR-TB patients were 
HIV positive (OR 2.6; 95% CI 1.7- 4). Strong association between becoming ill 
with MDR-TB and HIV positive were demonstrated during multivariate analysis 
(OR 3; 95% CI 1.2-5.6).  The risk of becoming ill with MDR-TB is 3 times higher 
among TB/HIV co-infected individuals. 
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Figure 4.4 HIV status of MDR-TB (n=113) and non MDR-TB (n=326)  
 
Table 4.6: Socio-demographic characteristics and patient related factors 
of MDR and non MDR-TB patients (n=439) 
Characteristics  Crude OR  
(95% CI) 
p-value Adjusted OR
a
 
(95% CI) 
p-value 
Gender:  
             Male 
             Female 
 
1.76 (1.13-
2.74) 
 
0.012 
 
2 (1.035-5)  
1.00 
 
0.039 
Geographical location of 
residence: 
Urban 
Rural 
 
 
2.7 (1.35-5.5) 
1.00 
 
 
0.005 
 
 
1.6 (0.5-5) 
1.00 
 
 
0.396 
Previous history of TB 
treatment: 
Yes 
No 
 
 
75(38-148) 
1.00 
 
 
0.00 
 
 
112 (47-267) 
1.00 
 
 
0.00 
Number of times TB 
treatment used: 
        Once 
       ≥2 times 
 
 
1.00 
10 (3.8-27) 
 
 
 
0.00 
 
 
0.00 
1.7 (1.03-34) 
 
 
 
0.024 
Previous category of TB     
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treatment: 
 Failure of first treatment 
 Relapse 
 Return after default 
Failure after re-treatment 
Not known 
 
3.17 (0.36-27) 
0.4 (0.05-3.5) 
2 (0.09-44) 
17 (2-158) 
1.00 
 
0.297 
0.409 
0.661 
0.011 
 
0.29 (0.91-7) 
0.23 (0.15-8.1) 
19 (0.31-103) 
31 (11-63) 
 
 
0.741 
0.260 
0.29 
0.003 
 
Outcome of previous 
treatment: 
  Failure 
  Defaulted 
Treatment completed  
 
 
36 (7-187) 
0.7 (0.13-3.7) 
1.00 
 
 
0.00 
0.683 
 
 
 
29(1.93-6) 
1.7(0.29-0.973) 
1.00 
 
 
0.00 
0.871 
Site of TB involvement:  
 Pulmonary  
Extra-pulmonary 
 
3.9 (2-7.3) 
1.00 
 
 
0.00 
 
2(6-23) 
0.00 
 
0.00 
Acid Fast Bacilli (AFB) 
smear for current TB 
treatment: 
Positive 
Negative 
 
 
 
5(3.3-9) 
1.00 
 
 
 
0.00 
 
 
 
8 (3.5-19) 
 
 
 
0.000 
Result of HIV test: 
Positive 
Negative 
 
2.6(1.7- 4) 
1.00 
 
0.00 
 
3 (1.2-5.6) 
1.00 
 
0.012 
a
The data were analysed using bi-variate and multivariate logistic regression. 
Each odds ratio has adjusted for all other characteristics in the table.  
OR-odds ratio, CI-confidence interval 
 
In conclusion, bivariate analysis and subsequent multivariate analysis of male 
gender, two or more times previous history of TB treatment, previous category 
of failure after re-treatment, failed TB treatment outcome, sputum smear 
positive pulmonary TB and being HIV positive were significantly associated with 
the risks of becoming ill with MDR-TB. 
 
4.5 CONCLUSION  
 
This chapter discussed the data analysis and interpretation of the findings with 
reference to the literature review where needed. The results were presented in 
tables and figures.  
 
Chapter 5 concludes the study by discussing the limitations and makes 
recommendations for practice and further research. 
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CHAPTER 5 
 
Conclusions, limitations and Recommendations 
 
5.1 INTRODUCTION  
 
The purpose of this study was to investigate the risk factors for MDR-TB in 
Addis Ababa, Ethiopia. Data on risk factors contributing for the occurrence of 
MDR-TB can be used in designing educational messages that can improve 
health care seeking towards MDR-TB. The findings could provide important 
information on ways to improve quality of MDR-TB care in the country.   
 
5.2 RESEARCH DESIGN AND METHODOLOGY 
 
Tuberculosis (TB) is one of the leading causes of morbidity, the fourth causes of 
hospital admissions, and the second cause of hospital deaths in Ethiopia 
(FMOH 2009: 1). The Ethiopian government policy makes provision for free 
care to TB patients, including consultation, laboratory services and non-
payment for drugs. Despite these services the public health concern of MDR-TB 
is raising in the country, factors underlying for spread of this diseases is not yet 
determined. The study aims to investigate the risk factors for MDR-TB. The 
researcher adopted a quantitative approach, using a comparative cross-
sectional study design to investigate the risk factors for emerging public health 
problem of MDR-TB in Addis Ababa.  
 
The study population comprised MDR-TB and non MDR-TB patients who were 
registered between January 2008 to December 2011 and taking their treatment 
in 26 public health centres in Addis Ababa. A total of 439 medical records of TB 
patients were included in this study, 113 MDR-TB and 326 non MDR-TB 
patients. Data were transcribed from each TB patient‟s medical records using a 
specifically designed checklist.  
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5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS 
 
The findings are discussed according to the 4 objective of the study. The 
specific objectives of the study were to:  
o To determine the socio-demographic factors associated with MDR-TB 
among patients in Addis Ababa. 
o To determine if non adherence to treatment is associated with 
development MDR-TB. 
o To determine the types of TB treatment categories and treatment 
outcomes associated with MDR-TB.  
o To determine the association of HIV/AIDS and MDR-TB in Addis Ababa.  
 
5.3.1: To determine the socio-demographic factors associated with the 
risk of MDR-TB  
 
5.3.1.1: Socio-demographic factors of MDR-TB and non MDR-TB patients  
 
5.3.1.1.1: Gender as a risk factor for MDR-TB 
 
The result showed that MDR-TB is more common among men. These results 
are similar to those that were reported by Molly et al (2008:4) in a study carried 
out in Peru. Stronger association of being a male sex as a risk factor for MDR-
TB is found in other studies such as those undertaken by Faustini et al 
(2006:161). WHO (2010:12) corroborate male gender was associated with the 
risk of becoming ill with MDR-TB.  
 
Muayad et al (2011: 517) described the higher prevalence of MDR-TB in men 
over women may be explained by the fact that women are more compliant with 
treatment and therefore less likely to receive inadequate treatment than men. 
Furthermore, men are almost always outdoors and therefore more susceptible 
to community-acquired resistant strains.  
 
5.3.1.1.2: Age as a risk factor for MDR-TB 
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More than 60% of both MDR and non-MDR patients were 15-34 years old. 
There was no statistically significant age difference between MDR and non-
MDR patients. But the concentration of MDR-TB is shown to be high among 
young adults aged 15-34 years. Similarly the highest toll of MDR-TB is shown in 
a report of study by W. S. Law et al (2008:1065) including WHO (2010:4), i.e., 
younger age was found to be the significant contributor for development of 
MDR-TB.  Waseem et al (2009:21)) showed seventy-two percent of the MDR-
TB patients were young men with mean age of 32.28±8.7 yrs. But, similar study 
conducted in South Africa, Scott et al (2010:3) showed that age was not a 
significant risk factor.  
 
5.3.1.1.3: Role of geographical location of patients in relation to health facilities  
 
The results of this study showed that there is no association between 
geographical location of residence of being urban or rural and risk of becoming 
ill with MDR-TB. But in Georgia, Vashakidze et al (2009: 5) found living in 
densely populated capital city were risk factor for becoming ill with MDR-TB.   
 
5.3.2: To determine if non adherence to treatment is associated with 
development MDR-TB 
 
5.3.2.1: TB treatment adherence status  
 
There was significant association between acquiring MDR-TB and non-adhering 
to TB treatment. These results are similar to the study reported by W. S. Law et 
al (2008: 1066).   
 
There is significant association between acquiring MDR-TB and missing TB 
medication during intensive phase. This study suggests that there is a need to 
improve the knowledge of patients on TB treatment adherence to reduce the 
occurrence of MDR-TB. Besides there were a large percentage of records with 
unknown treatment outcome status among MDR-TB patients, indicating 
inadequate record-keeping practices by some healthcare providers.  This might 
have also resulted from high rate of treatment defaulting among these patients. 
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5.3.3: To determine the types of TB treatment categories and outcomes 
associated with MDR-TB 
 
5.3.3.1: Previous history of TB treatment 
 
 There was a significant association between previous history of TB treatment 
and the risk of becoming ill with MDR-TB. In Estonia, Kiliman (2009:64) also 
found previous history of TB treatment as significant contributor for occurrence 
of MDR-TB. According to Kai et al (2009: 770), Alistair et al (2010: 268) and 
WHO (2010:10) discloses patients who received previous anti-tuberculosis 
treatment had a 4-fold increased odds of acquiring multidrug resistance and 
prior exposure to anti-TB drugs is a well-established risk factor for drug 
resistance. 
 
5.3.3.2: Previous category of TB treatment  
 
There was a significant association between acquiring MDR-TB and previous 
treatment outcome of failure after re-treatment. Patients who fail after re-treated 
for TB were 31 fold riskier in developing MDR-TB relative to other treatment 
categories (those who failed after first time treatment, those who returned after 
defaulting and those with relapse). This supports the findings in a study 
conducted by D‟souza et al (2009: 9), which found strong association of MDR-
TB in those fails TB re-treatment. This suggests a need for clear medication 
guide and provision constant reminders for patients during their DOTs to 
prevent acquisition of MDR-TB. Similarly, priority should be given for routine 
DST among TB retreatment cases to make early diagnosis of MDR-TB.  
 
5.3.3.3: Number of times treated for TB  
 
There was strong statistical association between frequency of TB treatment and 
the risk of developing MDR-TB. Those patients who were treated for TB more 
than two or more times were 1.7 times more likely to be at risk of developing 
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MDR-TB in comparison to those who were treated less frequently. This might 
be due to high chances of defaulting of TB patients from treatment. This result 
is similar with the finding of Waseem et al (2009:21). In Pakistan, Fazli et al 
(2009: 163) found 20% of the MDR-TB patients used anti-TB treatment course 
once, 53.3% twice and 26.7% three times in the past and  80% used twice or 
more times.  
 
5.3.3.4: Previous TB treatment outcome  
 
91% (90) of MDR-TB had failure TB treatment outcome compared to 21% (6) 
among non MDR-TB patients. The remaining 6% (6) of the MDR and 61% (17) 
of the non MDR-TB patients had defaulted from previous treatment. This shows 
a strong association between TB treatment failure and risk of becoming ill with 
MDR-TB. Those patients who were previously failed their treatment were 29 
times more likely to develop MDR-TB in comparison to those who were not 
failed their TB treatment. In Republic of South Africa, Andrews et al (2010:4) 
found MDR and XDR-TB were strongly associated with a history of TB 
treatment failure. 
 
5.3.3.5: Site of TB involvement  
 
Based on these findings, it is plausible to assume that pulmonary involvement 
of TB is associated more with MDR-TB. Among thus, smear positive pulmonary 
TB patients were 2 times more likely to develop MDR-TB in comparison to 
smear negative pulmonary TB patients. Similarly, the study conducted in Hong 
Kong, China by S. Law et al (2008: 1066) showed vast majority of MDR-TB 
cases suffered from pulmonary TB (PTB) (98%). The study conducted in 
Tomsk, Russian Federation, Gelmanova et al (2007:705) discloses that sputum-
smear positivity was significantly associated with MDR-TB.  
 
5.3.4.1: TB/HIV co-infection  
 
There was strong association between TB and HIV co-infection and the risk of 
becoming ill with MDR-TB. TB/HIV co-infected patients in this study are 3 times 
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more likely to have MDR-TB infection than treatment sensitive TB or non MDR-
TB patients.  
This supports the findings of Gandhi et al (2010:82), conducted in South Africa, 
where 90% of patients with MDR-TB were co-infected with HIV. In a similar 
vein, the report of a study by Scott et al (2010:3) and Suchindran el al (2009:4) 
shown high percentage of MDR-TB among HIV infected individuals and higher 
odds of harbouring MDR-TB strains than TB patients for whom HIV negative.  
 
TB infected patients must be frequently screened for HIV and vice versa.  ARV 
therapy should be initiated for all TB patients as soon as possible.  A special 
attention must be given to selection of appropriate TB and ARV treatment 
regimens in order to avoid the risk of increased drug reaction and resistance. 
 
In general, the study indicated that male gender, poor TB treatment compliance, 
previous history of TB treatment, previous history of failed TB treatment, 
pulmonary involvement of TB infection, and TB/HIV co-infection were 
associated with the risk of MDR-TB acquisitions.  
 
5.4 LIMITATIONS OF THE STUDY 
 
The study is limited by its cross-sectional design and use of secondary data for 
analysis. A further limitation is that these findings cannot be directly generalised 
to all regions other than Addis Ababa because of socio-economical, 
epidemiological and health system related variations in TB and MDR-TB 
occurrences.  
 
The study does, however, provide important information about the common risk 
factors that influence the emergence of MDR-TB in Addis Ababa. This 
information would have critical benefit in TB patient education, improvement in 
quality of TB care and prevention of MDR-TB. 
 
5.5 RECOMMENDATIONS 
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On the basis of the findings of this study, the researcher makes the following 
recommendations that might be useful for addressing the risk factors for MDR-
TB that might be useful in actual practice and for further research. 
  
5.5.1 Practice 
 
 Effort should be increased to prioritise the development and 
implementation of effective MDR-TB screening and adherence to 
treatment protocols for those high risk groups to avoid the emergence of 
resistance. Patients with previous TB treatment history, those who had 
failure after re-treatment, those who developed TB treatment failure as 
an outcome, those who were treated for TB twice or more times, 
pulmonary TB cases, and TB/HIV co-infected individuals are some of the 
priority patient groups according to this study. 
 
 Health education should be strengthened on TB treatment adherence. A 
checklist must be used to ensure that no vital information is omitted; for 
example, the duration of treatment, when to take their medications, how 
to recognise and handle side effects, and importance of TB treatment 
compliance to prevent further becoming ill with MDR-TB.  
 Dedicated coordinators should be appointed to TB programs in health 
facilities. Frequent on-job trainings should be given for health care 
workers involved in TB management to improve recording and reporting.  
 
5.5.2 Further research  
 
Further research needs to be conducted on the following topics:  
A. National health system analysis to identify factors that favour the 
emergence of MDR-TB in Ethiopia.  
B. Review of the impact of HIV/AIDS on MDR-TB treatment outcome 
C. Case-control study to assess reasons why males are more at risk of 
becoming ill with MDR-TB 
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5.6 CONCLUSION  
 
This chapter concluded the study by discussing its limitations and by making a 
variety of recommendations on the basis of the results obtained from the study. 
These can be used to address the risk factors for MDR-TB and they can also be 
used in further research that addresses MDR-TB prevention and patient 
management with MDR-TB. The prevention of this lethal public health problem 
of MDR-TB requires combined effort of all stake holders, namely the 
government, the health care workers, patient and community to tackle the 
problem. The researcher is of the opinion that this study will contribute 
significantly to alleviating the problem of TB and identified risk factors for MDR-
TB. 
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